# ASCO 2026
Latest news and articles about ASCO 2026
Total: 3 articles found
Bispecific Ambition: Akeso’s Ivonescimab Challenges the Oncology Hierarchy in Chicago
Akeso Biopharma’s ivonescimab has demonstrated a significant survival advantage over traditional PD-1 therapies in a landmark Phase III lung cancer trial. While the results signal a shift toward bispecific antibodies as the new standard, experts caution that further global data and longer follow-up are needed to solidify its dominance.
China’s Oncology Vanguard: Biotech Innovations Take Center Stage at ASCO 2026
Chinese biotech firms and researchers have achieved a record-breaking presence at the 2026 ASCO Annual Meeting, with 95 abstracts selected for major sessions. Led by STAR Market innovators like BeiGene and Biokin, this surge reflects China's transition from a generic-drug manufacturer to a global leader in high-impact oncology research.
The New Vanguard: China’s Biotechs Shift from Mimicry to Mastery at ASCO 2026
China has achieved a record-breaking presence at the 2026 ASCO conference, securing nearly 20% of the world's Late-Breaking Abstracts. This surge reflects a decade-long transition from generic drug manufacturing to leading-edge oncology innovation in fields like ADCs and bispecific antibodies.